Assessment of non-cirrhotic portal hypertension associated with thiopurine therapy in inflammatory bowel disease

Journal of Crohn's and Colitis

Volumn 5, Issue 1, 2011, Pages 48-53

  Calabrese, Emma ^a   Hanauer, Stephen B ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

6 tioguanine; Azathioprine; Hepatotoxicity; Nodular regenerative hyperplasia; Thiopurine

Indexed keywords

MERCAPTOPURINE; NADOLOL; PREDNISONE; WARFARIN;

ADULT; ARTICLE; CASE REPORT; CLINICAL FEATURE; CROHN DISEASE; DRUG WITHDRAWAL; ENDOSCOPY; ENTERITIS; ESOPHAGUS VARICES; HUMAN; LIVER BIOPSY; LIVER TOXICITY; MALE; NODULAR HYPERPLASIA; PORTAL HYPERTENSION; PRIORITY JOURNAL; TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT; TREATMENT OUTCOME;

6-MERCAPTOPURINE; AZATHIOPRINE; CROHN DISEASE; HUMANS; HYPERTENSION, PORTAL; IMMUNOSUPPRESSIVE AGENTS; LIVER; MALE; MIDDLE AGED;

EID: 78951490505     PISSN: 18739946     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.crohns.2010.08.007     Document Type: Article

References (49)

1. Bouhnik Y., Lemann M., Mary J.Y., Scemama G., Taï R., Matuchansky C., et al. Long-term follow-up of patients with Crohn's disease treated with azathioprine or 6-mercaptopurine. Lancet 1996, 347:215-219.
2. Cuffari C., Theoret Y., Latour S., Seidman G. 6-Mercaptopurine metabolism in Crohn's disease: correlation with efficacy and toxicity. Gut 1996, 39:401-406.
3. Korelitz B.I., Adler D.J., Mendelsohn R.A., Sancknoff A.L. Long-term experience with 6-mercaptopurine in the treatment of Crohn's disease. Am J Gastroenterol 1993, 88:1198-1205.
4. Korelitz B.I., Present D.H. Favorable effect of 6-mercaptopurine on fistulae of Crohn's disease. Dig Dis Sci 1985, 30:58-64.
5. Prefontaine E., Macdonald J.K., Sutherland L.R. Azathioprine or 6-mercaptopurine for induction of remission in Crohn's disease. Cochrane Database Syst Rev 2009, CD000545.
6. Present D.H., Korelitz B.I., Wisch N., Glass J.L., Sachar D.B., Pasternack B.S. Treatment of Crohn's disease with 6-mercaptopurine. A long-term, randomized, double-blind study. N Engl J Med 1980, 302:981-987.
7. Louis E., Belaiche J. Optimizing treatment with thioguanine derivatives in inflammatory bowel disease. Best Pract Res Clin Gastroenterol 2003, 17:37-46.
8. Jharap B., Seinen M.L., de Boer N.K., van Ginkel J.R., Linskens R.K., Kneppelhout J.C., et al. Thiopurine therapy in inflammatory bowel disease patients: Analyses of two 8-year intercept cohorts. Inflamm Bowel Dis 2010 Sep, 16(9):1541-1549.
9. Sandborn W.J. Azathioprine: state of the art in inflammatory bowel disease. Scand J Gastroenterol Suppl 1998, 225:92-99.
10. Sahasranaman S., Howard D., Roy S. Clinical pharmacology and pharmacogenetics of thiopurines. Eur J Clin Pharmacol 2008, 64:753-767.
11. Dubinsky M.C., Yang H., Hassard P.V., Seidman E.G., Kam L.Y., Abreu M.T., et al. 6-MP metabolite profiles provide a biochemical explanation for 6-MP resistance in patients with inflammatory bowel disease. Gastroenterology 2002, 122:904-915.
12. Dubinsky M.C., Lamothe S., Yang H.Y., Targan S.R., Sinnett D., Théorêt Y., et al. Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology 2000, 118:705-713.
13. Dubinsky M.C., Feldman E.J., Abreu M.T., Targan S.R., Vasiliauskas E.A. Thioguanine: a potential alternate thiopurine for IBD patients allergic to 6-mercaptopurine or azathioprine. Am J Gastroenterol 2003, 98:1058-1063.
14. Vernier-Massouille G., Cosnes J., Lemann M., Marteau P., Reinisch W., Laharie D., et al. Nodular regenerative hyperplasia in patients with inflammatory bowel disease treated with azathioprine. Gut 2007, 56:1404-1409.
15. Gisbert J.P., Gonzalez-Lama Y., Mate J. Thiopurine-induced liver injury in patients with inflammatory bowel disease: a systematic review. Am J Gastroenterol 2007, 102:1518-1527.
16. Benichou C. Criteria of drug-induced liver disorders. Report of an international consensus meeting. J Hepatol 1990, 11:272-276.
17. Fraser A.G., Orchard T.R., Jewell D.P. The efficacy of azathioprine for the treatment of inflammatory bowel disease: a 30 year review. Gut 2002, 50:485-489.
18. Bastida G., Nos P., Aguas M., Beltrán B., Rubín A., Dasí F., et al. Incidence, risk factors and clinical course of thiopurine-induced liver injury in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2005, 22:775-782.
19. Katzka D.A., Saul S.H., Jorkasky D., Sigal H., Reynolds J.C., Soloway R.D. Azathioprine and hepatic venocclusive disease in renal transplant patients. Gastroenterology 1986, 90:446-454.
20. Lemley D.E., DeLacy L.M., Seeff L.B., Ishak K.J., Nashel D.J. Azathioprine induced hepatic veno-occlusive disease in rheumatoid arthritis. Ann Rheum Dis 1989, 48:342-346.
21. Degott C., Rueff B., Kreis H., Duboust A., Potet F., Benhamou J.P. Peliosis hepatis in recipients of renal transplants. Gut 1978, 19:748-753.
22. Larrey D., Freneaux E., Berson A., Babany G., Degott C., Valla D., et al. Peliosis hepatis induced by 6-thioguanine administration. Gut 1988, 29:1265-1269.
23. Nataf C., Feldmann G., Lebrec D., Degott C., Descamps J.M., Rueff B., et al. Idiopathic portal hypertension (perisinusoidal fibrosis) after renal transplantation. Gut 1979, 20:531-537.
24. Arnott I.D., Ghosh S. Portal hypertension in the presence of minimal liver damage in Crohn's disease on long-term azathioprine: possible endothelial cell injury. Eur J Gastroenterol Hepatol 2000, 12:569-573.
25. Daniel F., Cadranel J.F., Seksik P., Cazier A., Duong Van Huyen J.P., Ziol M., et al. Azathioprine induced nodular regenerative hyperplasia in IBD patients. Gastroentérol Clin Biol 2005, 29:600-603.
26. Russmann S., Zimmermann A., Krahenbuhl S., Kern B., Reichen J. Veno-occlusive disease, nodular regenerative hyperplasia and hepatocellular carcinoma after azathioprine treatment in a patient with ulcerative colitis. Eur J Gastroenterol Hepatol 2001, 13:287-290.
27. Seiderer J., Zech C.J., Diebold J., Schoenberg S.O., Brand S., Tillack C., et al. Nodular regenerative hyperplasia: a reversible entity associated with azathioprine therapy. Eur J Gastroenterol Hepatol 2006, 18:553-555.
28. Haboubi N.Y., Ali H.H., Whitwell H.L., Ackrill P. Role of endothelial cell injury in the spectrum of azathioprine-induced liver disease after renal transplant: light microscopy and ultrastructural observations. Am J Gastroenterol 1988, 83:256-261.
29. Wanless I.R. Micronodular transformation (nodular regenerative hyperplasia) of the liver: a report of 64 cases among 2, 500 autopsies and a new classification of benign hepatocellular nodules. Hepatology 1990, 11:787-797.
30. Reshamwala P.A., Kleiner D.E., Heller T. Nodular regenerative hyperplasia: not all nodules are created equal. Hepatology 2006, 44:7-14.
31. Geller S.A., Dubinsky M.C., Poordad F.F., Vasiliauskas E.A., Cohen A.H., Abreu M.T., et al. Early hepatic nodular hyperplasia and submicroscopic fibrosis associated with 6-thioguanine therapy in inflammatory bowel disease. Am J Surg Pathol 2004, 28:1204-1211.
32. Dubinsky M.C., Vasiliauskas E.A., Singh H., Abreu M.T., Papadakis K.A., Tran T., et al. 6-thioguanine can cause serious liver injury in inflammatory bowel disease patients. Gastroenterology 2003, 125:298-303.
33. Seiderer J., Zech C.J., Reinisch W., Lukas M., Diebold J., Wrba F., et al. A multicenter assessment of liver toxicity by MRI and biopsy in IBD patients on 6-thioguanine. J Hepatol 2005, 43:303-309.
34. Laharie D., Vergniol J., Bioulac-Sage P., Diris B., Poli J., Foucher J., Couzigou P., et al. Usefulness of noninvasive tests in nodular regenerative hyperplasia of the liver. Eur J Gastroenterol Hepatol 2010, 22:487-493.
35. Jharap B., van Asseldonk D.P., de Boer N.K., Colombel J.F., Diebold J., Jonker A.M., et al. Low inter-observer agreement on nodular regenerative hyperplasia of the liver: an European inter-observer analysis. Gastroenterology 2010, 138:S456.
36. Buffet C., Cantarovitch M., Pelletier G., Fabre M., Martin E., Charpentier B., et al. Three cases of nodular regenerative hyperplasia of the liver following renal transplantation. Nephrol Dial Transplant 1988, 3:327-330.
37. Morris J.M., Oien K.A., McMahon M., Forrest E.H., Morris J., Stanley A.J., et al. Nodular regenerative hyperplasia of the liver: survival and associated features in a UK case series. Eur J Gastroenterol Hepatol 2010, 22(8):1001-1005.
38. De Boer N.K., Tuynman H., Bloemena E., Westerga J., Van Der Peet D.L., Mulder C.J., et al. Histopathology of liver biopsies from a thiopurine-naive inflammatory bowel disease cohort: prevalence of nodular regenerative hyperplasia. Scand J Gastroenterol 2008, 43:604-608.
39. Mion F., Napoleon B., Berger F., Chevallier M., Bonvoisin S., Descos L. Azathioprine induced liver disease: nodular regenerative hyperplasia of the liver and perivenous fibrosis in a patient treated for multiple sclerosis. Gut 1991, 32:715-717.
40. Stork L.C., Matloub Y., Broxson E., La M., Yanofsky R., Sather H., et al. Oral 6-mercaptopurine vs. Oral 6-thioguanine and veno-occlusive disease in children with standard risk acute lymphoblastic leukemia: report of the Children's Oncology Group CCG-1952 clinical trial. Blood 2010, 115(14):2740-2748.
41. Gilissen L.P., Derijks L.J., Driessen A., Bos L.P., Hooymans P.M., Stockbrügger R.W., et al. Toxicity of 6-thioguanine: no hepatotoxicity in a series of IBD patients treated with long-term, low dose 6-thioguanine. Some evidence for dose or metabolite level dependent effects?. Dig Liver Dis 2007, 39:156-159.
42. de Boer N.K., Zondervan P.E., Gilissen L.P., den Hartog G., Westerveld B.D., Derijks L.J., et al. Absence of nodular regenerative hyperplasia after low-dose 6-thioguanine maintenance therapy in inflammatory bowel disease patients. Dig Liver Dis 2008, 40:108-113.
43. Al Hadithy A.F., de Boer N.K., Derijks L.J., Escher J.C., Mulder C.J., Brouwers J.R. Thiopurines in inflammatory bowel disease: pharmacogenetics, therapeutic drug monitoring and clinical recommendations. Dig Liver Dis 2005, 37:282-297.
44. van Asseldonk D.P. Liver histology of IBD patients who are treated with 6-Thioguanine due to failure of conventional thiopurines reveals very few cases of nodular regenerative hyperplasia. Gastroenterology 2010, 138:S62.
45. DeLeve L.D., Wang X., Kuhlenkamp J.F., Kaplowitz N. Toxicity of azathioprine and monocrotaline in murine sinusoidal endothelial cells and hepatocytes: the role of glutathione and relevance to hepatic venoocclusive disease. Hepatology 1996, 23:589-599.
46. de Boer N.K., van Bodegraven A.A., Jharap B., de Graaf P., Mulder C.J. Drug Insight: pharmacology and toxicity of thiopurine therapy in patients with IBD. Nat Clin Pract Gastroenterol Hepatol 2007, 4:686-694.
47. Ferlitsch A., Teml A., Reinisch W., Ulbrich G., Wrba F., Homoncik M., et al. 6-thioguanine associated nodular regenerative hyperplasia in patients with inflammatory bowel disease may induce portal hypertension. Am J Gastroenterol 2007, 102:2495-2503.
48. Hillaire S., Bonte E., Denninger M.H., Casadevall N., Cadranel J.F., Lebrec D., et al. Idiopathic non-cirrhotic intrahepatic portal hypertension in the West: a re-evaluation in 28 patients. Gut 2002, 51:275-280.
49. Levy S., Diebold M.D., Nguyen P., Lirzin P., Thiéfin G. Nodular regenerative hyperplasia of the liver associated with a Factor V Leiden mutation. Eur J Gastroenterol Hepatol 1998, 10:721.